Evidence mapPaperPMID 36937888Full record

ArticleFrontiers in pharmacology2023

Emodin ameliorates renal injury and fibrosis

Liulin Wang, Xuerui Wang, Gang Li, Shanshan Zhou, Rui Wang, Qi Long, Min Wang, Liang Li, Hai Huang, Yuanming Ba

Open access · goldFull text read
In one paragraph

Article in Frontiers in pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Abietane-Type Diterpenoids from the Resin ofMolecules (Basel, Switzerland) · 2026
    Article
  6. Review
  7. Article
  8. Anthraquinones fromDrug design, development and therapy · 2025
    Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Liulin WangHubei Provincial Hospital of Tranditional Chinese Medicine, Wuhan, China.
Xuerui WangBeijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, China.
Gang LiHubei Provincial Hospital of Tranditional Chinese Medicine, Wuhan, China.
Shanshan ZhouHubei Provincial Hospital of Tranditional Chinese Medicine, Wuhan, China.
Rui WangHubei Provincial Hospital of Tranditional Chinese Medicine, Wuhan, China.
Qi LongHubei Provincial Hospital of Tranditional Chinese Medicine, Wuhan, China.
Min WangHubei Provincial Hospital of Tranditional Chinese Medicine, Wuhan, China.
Liang LiHubei Provincial Hospital of Tranditional Chinese Medicine, Wuhan, China.
Hai HuangHubei Provincial Hospital of Tranditional Chinese Medicine, Wuhan, China.
Yuanming BaHubei Provincial Hospital of Tranditional Chinese Medicine, Wuhan, China.
Hubei University · CNHubei Provincial Hospital of Traditional Chinese Medicine · CNBeijing Hospital of Traditional Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Renal fibrosis is a major pathological feature of chronic kidney disease (CKD). While emodin is reported to elicit anti-fibrotic effects on renal injury, little is known about its effects on microRNA (miRNA)-modulated mechanisms in renal fibrosis. In this study, we established a unilateral ureteral obstruction (UUO) model and a transforming growth factor (TGF)-β1-induced normal rat renal tubular epithelial cell line (NRK-52E) model to investigate the protective effects of emodin on renal fibrosis and its miRNA/target gene mechanisms. Dual-luciferase assay was performed to confirm the direct binding of miRNA and target genes in HEK293 cells. Results showed that oral administration of emodin significantly ameliorated the loss of body weight and the increase in physicochemical parameters, including serum uric acid, creatinine, and urea nitrogen in UUO mice. Inflammatory cytokines, including tumor necrosis factor-α, monocyte chemoattractant protein-1, and interleukin (IL)-1β, but not IL-6, were down-regulated by emodin administration. Emodin decreased the expression levels of TGF-β1 and fibrotic-related proteins, including alpha-smooth muscle actin, Collagen IV, and Fibronectin, and increased the expression of E-cadherin. Furthermore, miR-490-3p was decreased in UUO mice and negatively correlated with increased expression of high migration protein A2 (HMGA2). We further confirmed HMGA2 was the target of miR-490-3p. Transfection of miR-490-3p mimics decreased, while transfection of miR-490-3p inhibitors increased fibrotic-related proteins and HMGA2 expression levels in TGF-β1-induced NRK-52E cells. Furthermore, transfection of miR-490-3p mimics enhanced the anti-fibrotic effects of emodin, while transfection of miR-490-3p inhibitors abolished the protective effects of emodin. Thus, as a novel target of emodin that prevents renal fibrosis in the HMGA2-dependent signaling pathway, miR-490-3p has potential implications in CKD pathology.

Indexed as

emodinHMGA2inflammatory factormicroRNArenal fibrosis

Identifiers

PMID36937888
PMCPMC10020706
OpenAlexW4323045769

What Socratic holds

Textfull text, public
LicenceCC BY
measurements read52
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.